|display ongoing studies|
|Study||Ref.||Design||studied treatment||control treatment||patients||study risk of bias||sample sizes||Results||deaths E||viral clearance E||hospitalization or death E|
COVID-19 prophylaxis meta-analysis
|O'Brien (Part A: uninfected household contacts), 2021|
|RCT||casirivimab and imdevimab (Ronapreve, REGN-COV2)||placebo||COVID-19 prophylaxis||some concern||1240/1235||conclusif|
|1 study excluded by filtering options (1 RCT / 0 OBS)|
PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).